Co-founder and Chairman Corey Goodman Resigns from ALX Oncology Board
ALXO has more than doubled off its 52-week low of $0.41.
Summary
Corey Goodman, a co-founder and the Chairman of ALX Oncology, has resigned from the board and all committees for personal reasons, effective June 29. This leadership change follows an 8-K filed minutes prior to this news. While the company stated no disagreement on operations, the departure of a co-founder and Chairman is a notable event for a company of ALXO's size, despite recent positive news like securing a $50 million debt facility and promising drug trial results.
At the time of this announcement, ALXO was trading at $2.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $278.5M. The 52-week trading range was $0.41 to $2.66. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.